Profiles > Matthew V. Anderson

Profile jpeg

Matthew V. Anderson

T: 312.222.7506
F: 312.222.7526

Download vCard
Profile jpeg

Matthew V. Anderson is an associate at Rakoczy Molino Mazzochi Siwik LLP.  He is registered to practice before the United States Patent and Trademark Office and holds a Master of Science in biotechnology.

Mr. Anderson is involved in all areas of the firm’s patent litigation practice.  He handles patent infringement suits arising under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act, and also assists clients on various patent counseling matters.  He has experience with every phase of litigation, including pre-suit investigation, fact discovery, expert discovery, pre-trial preparation, trial, and the appellate process.

Patent Counseling
Mr. Anderson has experience evaluating patent portfolios and providing opinions of counsel in a variety of art areas.  He also has experience preparing and prosecuting patent applications in those fields.

Representative Matters
Merck Sharp & Dohme Corp. (f/k/a Schering Corp.) v. Apotex Inc., et al. (Fed. Cir. 2013): Member of team that successfully represented Apotex Inc. and Apotex Corp. at trial and on appeal in patent litigation against Merck Sharp & Dohme Corp. (f/k/a Schering Corp.) concerning patents related to Nasonex®, an inhaled nasal steroid product.  On appeal, the Federal Circuit affirmed the decision of non-infringement by the United States District Court for the District of New Jersey.

Janssen Prods., L.P., et al. v. Lupin Ltd., et al. (D.N.J. 2014): Representing Lupin Ltd., Lupin Pharmaceuticals, Inc., Mylan Pharmaceuticals Inc., and Mylan Inc. at trial and on appeal in patent litigation against Janssen Products, L.P. (a Johnson & Johnson company) concerning patents related to Prezista®, an HIV-protease inhibitor product.

ViiV Healthcare UK Ltd., et al. v. Lupin Ltd., et al. (D. Del. 2014): Representing Lupin Ltd. and Lupin Pharmaceuticals, Inc. in patent litigation against ViiV Healthcare UK Ltd. concerning patents related to Trizivir®, an HIV-inhibitor triple combination product.

AstraZeneca LP, et al. v. Breath Ltd./Watson Labs., Inc. (D.N.J. 2013): Representing Breath Ltd. and Watson Laboratories, Inc. in patent litigation against AstraZeneca concerning patents related to Pulmicort Respules®, an inhaled glucocorticosteroid product.

Previous Experience
Prior to joining Rakoczy Molino Mazzochi Siwik LLP, Mr. Anderson worked as Patent Counsel at the Oklahoma Medical Research Foundation and as a Disease Specialist for Merck & Co., Inc.  He also previously worked at Rush University Medical Center as a Laboratory Manager and Research Assistant.

Mr. Anderson completed his thesis on the Assessment of Cerebral Edema by T2 Weighted MRI and Histology During Intermittent Reperfusion Using the Intraluminal Thread Model of Stroke in Rats, and has presented at various conferences on a number of topics in the field of neuroscience‚Äč.